Transgene: visibility confirmed, catalysts to come

(CercleFinance.com) - Transgene announced on Wednesday that it has financial visibility through to Q4 2025, and expects to deliver significant clinical results by the end of the year.


At June 30, the French biotech had cash and cash equivalents of 15.3 million euros, compared with 15.7 million euros at the end of 2023.

The company, which develops immunotherapy products for the treatment of cancer, reports that its cash burn amounted to 20.4 million euros in the first half of the year, compared with 19.5 million euros in the same period of 2023.

In a press release, Transgene emphasizes that its assured financial visibility until the fourth quarter of 2025 will enable it to communicate important results on its portfolio of candidates in clinical development over the next 12 months.

On the operational front, the company points to several catalysts between now and the end of the year, including Phase I data on its TG4050 vaccine for the treatment of head and neck cancer.

Preliminary results from a Phase II trial evaluating TG4001 in HPV anogenital cancers and initial data from a Phase 1 trial on TG6050 in lung cancer are also expected during the fourth quarter.

Following these announcements, Transgene shares gained 0.6% on Wednesday on the Paris Bourse, compared with a decline of around 0.5% for the Paris market.

Copyright (c) 2024 CercleFinance.com. All rights reserved.